Previously trading on NASDAQ (from April 0213) - and then for period on OTC (OTC:BRTX) - BioRestorative Therapies traded again on NASDAQ (NASDAQ:BRTX) and now (Feb 2023) is again OTC.BRTX. Only recently SBIR involved, the firm is a life sciences company structured around development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100 that has completed Phase 1 clinical trials is a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow and intended for the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate, which is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue (BAT). In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a R&D agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. Originally dba as Stem Cell Assurance, Inc., the firm's name was changed to BioRestorative Therapies, Inc. in August 2011.
